Corcept Therapeutics INC

Corcept Therapeutics reports strong Q2 2026 results with revenue up 32% to $256.1 million, driven by Korlym and the new Lifyorli, and raises full-year revenue guidance.

Corcept Therapeutics has resubmitted its New Drug Application to the FDA for relacorilant to treat Cushing's syndrome, following FDA requests for additional data analysis.

Corcept Therapeutics announced the U.S. Department of Justice will not intervene in a civil lawsuit filed by a former employee.

Corcept Therapeutics stockholders approved an 8 million share increase to the 2024 Incentive Award Plan and re-elected all eight board directors.

Corcept Therapeutics reported Q1 2026 revenue of $164.9 million and raised its full-year revenue guidance to $950-$1,050 million following the FDA approval of Lifyorli.

Corcept Therapeutics announced FDA approval of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer.

Corcept Therapeutics reports strong revenue growth driven by Hypercortisolism Products and Lifyorli, while navigating regulatory reviews and ongoing litigation.

Corcept Therapeutics reported increased product revenue for Q3 and the nine months ended September 30, 2025, driven by higher sales volume, but net income declined due to significantly increased operating expenses and R&D investments.

Corcept Therapeutics reported increased product revenue driven by higher sales volume but experienced a decline in net income due to significantly higher operating expenses, while advancing key drug candidates with positive clinical trial results and new FDA submissions.

Corcept Therapeutics' Q1 2025 revenue increased, driven by higher sales volume, while the FDA accepted the NDA for relacorilant, a potential treatment for hypercortisolism.

Corcept Therapeutics reported a significant increase in product revenue for the third quarter of 2024, alongside updates on its clinical development programs.

Corcept Therapeutics reports a significant increase in second-quarter revenue, driven by higher sales volumes and a price increase, while also advancing its clinical programs.

Corcept Therapeutics reports strong 2025 revenue growth driven by Korlym sales, despite an FDA Complete Response Letter for relacorilant in hypercortisolism, while oncology programs show promising advancements.

Corcept Therapeutics achieved record revenue in 2024 and submitted a New Drug Application (NDA) to the FDA for relacorilant, a potential treatment for hypercortisolism.

Corcept Therapeutics' 2023 10-K filing reveals increased revenue, ongoing clinical trials, and legal challenges.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 80,000 shares of common stock on July 30, 2026.

James N Wilson, a Director of Corcept Therapeutics Inc, sold 10,000 shares of common stock on July 15, 2026.

Atabak Mokari, Chief Financial Officer of Corcept Therapeutics Inc, sold 40,000 shares of common stock on July 15, 2026.

Gary Charles Robb, Chief Business Officer at Corcept Therapeutics Inc., reported a transaction involving common stock on May 27, 2026.

Corcept Therapeutics Chief Development Officer William Guyer reported transactions involving company stock, including the acquisition of stock options and the sale of common stock.

Sean Maduck, President of Corcept Endocrinology, engaged in significant stock transactions, including acquisitions and sales, on July 1, 2026, under a Rule 10b5-1 plan.

Corcept Therapeutics has issued its 2026 proxy statement detailing director elections, executive compensation, and a proposal to increase shares under its 2024 Incentive Award Plan.

Corcept Therapeutics will hold its annual stockholder meeting on June 10, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.

Corcept Therapeutics issues a supplement to its proxy statement to correct the number of outstanding shares of common stock as of the record date for the upcoming annual meeting.

Corcept Therapeutics will hold its annual stockholders meeting on May 17, 2024, to vote on director elections, auditor ratification, executive compensation, and a new incentive award plan.

Investment firm Ingalls & Snyder LLC has reported a 6.8% beneficial ownership stake in Corcept Therapeutics Inc.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Corcept Therapeutics Inc. following an internal realignment.

Renaissance Technologies LLC and its parent company have reported a 5.47% beneficial ownership stake in Corcept Therapeutics Incorporated.

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, disclosing a 10.9% beneficial ownership stake in Corcept Therapeutics Incorporated as of June 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 12.7% of Corcept Therapeutics Inc.'s common stock as of March 31, 2025.

Investment firm Ingalls & Snyder LLC has disclosed a passive beneficial ownership of 7.8% of Corcept Therapeutics Inc.'s common stock as of December 31, 2024.